VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma.
Alexander EnglischBianca AltvaterSareetha KailayangiriWolfgang HartmannClaudia RossigPublished in: Pediatric blood & cancer (2020)
VEGFR2 is consistently expressed on endothelial cells of the tumor stroma in EwS and thus is a candidate target for CAR T cells in this cancer. Among various VEGFR2-specific CARs, a construct with a short hinge domain was chosen to be further developed toward clinical translation.